Asunto(s)
Abiotrophia/aislamiento & purificación , Válvula Aórtica/microbiología , Endocarditis Bacteriana/microbiología , Infecciones por Bacterias Grampositivas/microbiología , Válvula Mitral/microbiología , Antibacterianos/uso terapéutico , Válvula Aórtica/patología , Dispositivos para el Autocuidado Bucal/efectos adversos , Endocarditis Bacteriana/tratamiento farmacológico , Endocarditis Bacteriana/patología , Femenino , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/patología , Humanos , Persona de Mediana Edad , Válvula Mitral/patología , Resultado del TratamientoRESUMEN
B virus (Cercopithecine herpesvirus 1) is a zoonotic agent that can cause fatal encephalomyelitis in humans. The virus naturally infects macaque monkeys, resulting in disease that is similar to herpes simplex virus infection in humans. Although B virus infection generally is asymptomatic or mild in macaques, it can be fatal in humans. Previously reported cases of B virus disease in humans usually have been attributed to animal bites, scratches, or percutaneous inoculation with infected materials; however, the first fatal case of B virus infection due to mucosal splash exposure was reported in 1998. This case prompted the Centers for Disease Control and Prevention (Atlanta, Georgia) to convene a working group in 1999 to reconsider the prior recommendations for prevention and treatment of B virus exposure. The present report updates previous recommendations for the prevention, evaluation, and treatment of B virus infection in humans and considers the role of newer antiviral agents in postexposure prophylaxis.